More Articles

China approves bevacizumab copy biological Ankada Biosimilars/News | Posted 31/01/2020

China’s National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), announced on 9 December 2019 that it had approved Ankada, a bevacizumab copy biologi...

FDA approves generics for cancer and gout Generics/News | Posted 31/01/2020

The US Food and Drug Administration (FDA) has approved two generic versions of Novartis’ anticancer drug Afinitor (everolimus), alongside a generic of Takeda’s gout treatment Uloric (febuxostat).

DIA 2020 Global Annual Meeting Conferences | Posted 31/01/2020

DIA 2020 Global Annual Meeting 14–18 June 2020 Washington, DCUSA

Swiss position statement on the use of biosimilars in IBD Biosimilars/Research | Posted 24/01/2020

Experts from the Swiss Society of Gastroenterology have provided a position statement on the use of biosimilars in inflammatory bowel disease (IBD). The position paper summarizes key regulatory and...

Mundipharma and Samsung Bioepis partner for biosimilars in Hong Kong and Taiwan Pharma News | Posted 24/01/2020

Mundipharma announced on 13 January 2020 that it had entered into a partnership with Korea-based Samsung Bioepis (Samsung and Biogen’s joint venture) to commercialize four biosimilar candidates fro...

Teriparatide biosimilar Terossa approved in South Korea Biosimilars/News | Posted 24/01/2020

South Korea-based Daewon Pharmaceutical has obtained regulatory approval to begin marketing and selling its teriparatide biosimilar in Korea.

Eli Lilly and Novo Nordisk launches lower-priced insulin options Biosimilars/General | Posted 24/01/2020

Originator insulin makers Eli Lilly and Novo Nordisk have both announced the introduction of additional reduced cost insulin options for patients.

FDA sets up centre to improve quality of compounded drugs Generics/General | Posted 24/01/2020

The US Food and Drug Administration (FDA) has established a Center of Excellence to improve the quality of compounded drugs, which are created by combining two or more drugs and are not FDA-approved.